Mazindol
| Clinical data | |
|---|---|
| Trade names | Mazanor, Sanorex |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 93% |
| Metabolism | Hepatic |
| Elimination half-life | 10–13 hours |
| Excretion | Renal |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.040.764 |
| Chemical and physical data | |
| Formula | C16H13ClN2O |
| Molar mass | 284.74 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
SMILES
| |
InChI
| |
| (verify) | |
Mazindol, sold under the brand names Mazanor and Sanorex, is a central nervous system (CNS) stimulant which is used as an appetite suppressant.[2] It was developed by Sandoz-Wander in the 1960s.[3] The US Food and Drug Administration approved mazindol in June 1973, but Novartis, the manufacturer, discontinued it in 1999 for reasons unrelated to its efficacy or safety.[4]
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ Carruba MO, Zambotti F, Vicentini L, Picotti GB, Mantegazza P (1978). "Pharmacology and biochemical profile of a new anorectic drug: mazindol". Cent. Mech. Anorectic Drugs: 145–64.
- ^ Cite error: The named reference
US3597445was invoked but never defined (see the help page). - ^ "Determination That SANOREX (Mazindol) Tablets 1 and 2 Milligrams Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness". Federal Register. 15 July 2008. Retrieved 28 December 2024.